Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Hydromorphone price, strengths & recalls

Pharmacies pay $6.61 for 30 tablets of Hydromorphone 4 mg tablet this week, and from $5.12 to $371.41 across its 10 priced strengths and forms. 15 manufacturers make it. It is in shortage (unavailable). 3 recalls are ongoing. Its official label last changed on August 28, 2026.

Unavailable3 open recallsGeneric
Pharmacies pay$6.61for 30 tablets of 4 mg tablet+0.5% in 4 weeks
Fair cash price
$18.10
Strengths
10
Makers
15
Updated
Nov 11

Hydromorphone price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
2 mg/mL, 1 mL cartridgeNot priced this week
8 mg (24 hr) extended-release tablet$5.71$171.43 / 30 tablets-0.3%-10.7%
12 mg (24 hr) extended-release tablet$10.58$317.48 / 30 tablets+1.6%+0.4%
16 mg (24 hr) extended-release tablet$12.38$371.41 / 30 tabletsNo change+29.3%
2 mg/mL injectionNot priced this week
2 mg/mL, 1 mL injection$2.74$68.51 / 25 mLNo change-0.7%
10 mg/mL, 5 mL injection$2.57$128.31 / 50 mLNo change
10 mg/mL, 50 mL injection$2.57$128.31 / 50 mLNo change
1 mg/mL oral solution$0.2341$110.71 / 473 mL-0.8%-21.3%
3 mg suppositoryNot priced this week
2 mg tablet$0.1708$5.12 / 30 tablets+0.8%+2.2%
4 mg tablet$0.2202$6.61 / 30 tablets+0.5%+14.8%
8 mg tablet$0.5490$16.47 / 30 tablets-2.1%-1.7%

The lowest cost per tablet is 2 mg tablet at $0.1708. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Supply status: shortages & recalls

In shortage27 products are short or being discontinued
3 ongoing recalls189 recalls on record, latest Oct 22, 2025

Shortages

  • Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)Hospira, Inc., a Pfizer Company · Available · Updated Nov 9, 2026
  • Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)Hospira, Inc., a Pfizer Company · Limited Availability · Reason: Other · Updated Nov 9, 2026Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
  • Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)Hospira, Inc., a Pfizer Company · Available · Updated Nov 9, 2026
  • Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)Hospira, Inc., a Pfizer Company · Available · Updated Nov 9, 2026
  • Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)Hospira, Inc., a Pfizer Company · Available · Updated Nov 9, 2026
  • Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)Hospira, Inc., a Pfizer Company · Available · Updated Nov 9, 2026
  • Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)Hospira, Inc., a Pfizer Company · Limited Availability · Reason: Demand increase for the drug · Updated Nov 9, 2026Limited Supply Available. Next Delivery and Estimated Recovery: December 2026
  • Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)Hospira, Inc., a Pfizer Company · Unavailable · Reason: Other · Updated Nov 9, 2026Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
  • Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)Hospira, Inc., a Pfizer Company · Available · Updated Nov 9, 2026
  • Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)Hospira, Inc., a Pfizer Company · Unavailable · Reason: Other · Updated Nov 9, 2026Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
  • Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)Hospira, Inc., a Pfizer Company · Limited Availability · Reason: Other · Updated Nov 9, 2026Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
  • Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)Fresenius Kabi USA, LLC · Available · Updated Nov 3, 2026Check wholesalers for inventory

In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.

Recalls

Showing the 6 most relevant of 189 - all recalls.

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for hydromorphone? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedAugust 28, 2026
Version7 of 7
EffectiveJul 15, 2026
Read the label

These highlights do not include all the information needed to use HYDROMORPHONE HYDROCHLORIDE INJECTION and HYDROMORPHONE HYDROCHLORIDE INJECTION (HPF) safely and effectively.See full prescribing information for HYDROMORPHONE HYDROCHLORIDE INJECTION and HYDROMORPHONE HYDROCHLORIDE INJECTION (HPF). HYDROMORPHONE HYDROCHLORIDE injection and HYDROMORPHONE HYDROCHLORIDE injection [high potency formulation (HPF)], for intravenous, intramuscular, or subcutaneous use, CIIInitial U.S. Approval: January

This drug has a boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE INJECTION AND HYDROMORPHONE HYDROCHLORIDE INJECTION (HPF)

Risk of Medication Errors

Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] is a more concentrated solution of hydromorphone than Hydromorphone Hydrochloride Injection, and is for use in opioid-tolerant patients only. Do not confuse Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] with standard parenteral formulations of Hydromorphone Hydrochloride Injection or other opioids, as overdose and death could result [see Warnings and Precautions (5.1)].

Addiction, Abuse, and Misuse

Because the use of Hydromorphone Hydrochloride Injection and Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.2)].

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of

Hydromorphone Hydrochloride Injection or Hydromorphone Hydrochloride Injection [high potency formulation (HPF)], especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Hydrochloride Injection and Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] are essential [see Warnings and Precautions (5.3)].

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of Hydromorphone Hydrochloride Injection or Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions (5.4), Drug Interactions

(7)].

Neonatal Opioid Withdrawal Syndrome (NOWS)

Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery [see Warnings and Precautions (5.5)].

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE INJECTION AND HYDROMORPHONE HYDROCHLORIDE INJECTION (HPF)

See full prescribing information for complete boxed warning.

•

Do not confuse Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] with standard parenteral formulations of Hydromorphone Hydrochloride Injection or other opioids, as overdose and death could result. (5.1)

•

Hydromorphone Hydrochloride Injection and Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions. (5.2)

•

Serious, life-threatening, or fatal respiratory depression may occur, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Hydromorphone Hydrochloride Injection or Hydromorphone Hydrochloride Injection (HPF) are essential. (5.3)

•

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. (5.4, 7)

•

Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery. (5.5)

Recent major changes (as listed on the label)

Boxed Warning 12/2025

Indications and Usage (1) 12/2025

Dosage and Administration (2.6) 12/2025

Warnings and Precautions (5.2, 5.3, 5.4, 5.11, 5.13) 12/2025

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA019892 · Rhodes Pharms
First approved
December 7, 1992 (34 years ago)
Latest approved change
June 18, 2026
Approved label
PDF, Jan 6, 2026
Generic makers
9 approved generic applications on the market

Hydromorphone questions

How much does hydromorphone cost without insurance?

Pharmacies pay about $6.61 for 30 tablets of hydromorphone 4 mg tablet ($0.2202 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $18.10. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is hydromorphone in shortage?

Yes. 27 products are listed as in shortage or being discontinued (unavailable). See which ones.

Has hydromorphone been recalled?

189 recalls on record, 3 ongoing. Recalls name specific lots - check yours.

When did the hydromorphone label last change?

The official label was last updated on August 28, 2026 (version 7). See what changed.

Talk about hydromorphone

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.